Valeant to Rule Derm Market in $2.6B Medicis Acquisition
When J. Michael Pearson, CEO of Valeant Pharmaceuticals International Inc., reached out to Medicis Pharmaceuticals International Inc. to discuss terms for a potential merger, it was the third time the two companies had had such discussions in the last 18 months. In previous talks, the value of Medicis' broad-spectrum tetracycline antibiotic, Solodyn (minocycline), had been a sticking point.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST